Skip to main content
. Author manuscript; available in PMC: 2023 Apr 15.
Published before final editing as: Eur J Cancer. 2021 Oct 15;158:99–110. doi: 10.1016/j.ejca.2021.09.010

Table 2:

Incidence rate ratios for VTE events within two years pre-and post-immune checkpoint inhibitors (n=2854)

Pre-Immune Checkpoint Inhibitor Post-Immune Checkpoint Inhibitor
Number of events Incidence rate (per 100 person-years) Number of events Incidence rate (per 100 person-years)
Deep Vein Thrombosis 126 2.30 155 7.37
Pulmonary Embolism 162 2.95 140 6.61
Venous Thromboembolism 259 4.85 244 11.75